Cholinergic therapies for Alzheimer's disease target the cholinergic system, which is significantly impaired in AD due to degeneration of basal forebrain cholinergic neurons. The primary approach involves acetylcholinesterase (AChE) inhibition to increase synaptic acetylcholine levels, compensating for lost cholinergic signaling.
The cholinergic hypothesis of AD, proposed in the 1970s, remains clinically validated with three FDA-approved acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) representing the standard of care for symptomatic cognitive benefits.
FDA-Approved Cholinergic Therapies
Donepezil (Aricept)
Company: [Eisai](/organizations/eisai) (co-developed with Pfizer)
First approved in 1996 for mild-to-moderate AD
Once-daily oral formulation
Selective AChE inhibitor with minimal GI side effects
Available in 5mg, 10mg, and 23mg (Aricept 23mg for severe AD) doses
Cholinergic therapies for Alzheimer's disease target the cholinergic system, which is significantly impaired in AD due to degeneration of basal forebrain cholinergic neurons. The primary approach involves acetylcholinesterase (AChE) inhibition to increase synaptic acetylcholine levels, compensating for lost cholinergic signaling.
The cholinergic hypothesis of AD, proposed in the 1970s, remains clinically validated with three FDA-approved acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) representing the standard of care for symptomatic cognitive benefits.
FDA-Approved Cholinergic Therapies
Donepezil (Aricept)
Company: [Eisai](/organizations/eisai) (co-developed with Pfizer)
First approved in 1996 for mild-to-moderate AD
Once-daily oral formulation
Selective AChE inhibitor with minimal GI side effects
Available in 5mg, 10mg, and 23mg (Aricept 23mg for severe AD) doses
Rivastigmine (Exelon)
Company: [Novartis](/organizations/novartis)
Approved in 2000 for mild-to-moderate AD
Twice-daily oral and once-daily patch formulations
Dual AChE and butyrylcholinesterase (BuChE) inhibitor
Particularly effective in patients with more advanced disease (higher BuChE activity)
neurodegeneration Pipeline - Multi-target approaches combining AChE inhibition with other mechanisms
Market Landscape
The global AD cholinergic therapy market is valued at approximately $4-5 billion annually, with donepezil being the most widely prescribed. Key market trends include:
Patent expirations driving generic competition
Focus on disease modification shifting investment away from symptomatic treatments
Combination therapy development as companies seek to enhance efficacy
Novel delivery systems (transdermal patches, nanoparticles) improving patient compliance
Therapeutic Pipeline Summary
Mermaid diagram (expand to render)
Related Mechanisms
[Acetylcholine Signaling in Neurodegeneration](/mechanisms/acetylcholine-signaling-neurodegeneration)